2025-01-21
Recently, Great Bay Bio (GBB) partnered with Professor JZ Chen from the Koch Institute for Integrative Cancer Research at MIT to advance the discovery of a novel tumor-targeting antibody. This partnership aims to provide innovative antibody drug solutions for treating multiple solid tumors. This collaboration marks a new milestone for GBB in the application of cutting-edge international biotechnology.
This collaboration combines GBB's applied advantages in the field of drug discovery with the extensive expertise of Professor Chen in tumor-specific antibody discovery. Together, we aim to drive the discovery of novel antibodies targeting tumor antigens and accelerate the development of innovative therapeutic solutions for various solid tumors.
GBB is a biotech company that
drives drug development using advanced technologies such as AI, big data
mining, and automation, with a vision of “Global Bioprocessing Made Simpler and
More efficient." In the process of internationalization, GBB has
established partnerships with several MNCs in the life sciences, specialty
chemicals, and pharmaceutical CDMO sectors. Additionally, GBB has launched the
world’s first commercialized site-specific integration cell line development
platform (AlfaCell), which has enabled customers to secure clinical trial
approvals from both China’s National Medical Products Administration (NMPA) and
the U.S. Food and Drug Administration (FDA).
Professor Chen is professor of biology at MIT, Singapore Research
Professor, and intramural faculty at the Koch Institute. He is dedicated to
studying the immune system and its applications in cancer immunotherapy and
vaccine development. He has extensive research experience in immunology,
molecular and cellular mechanisms, humanized mice, and target discovery, and
antibody-mediated therapies. Professor Chen has published numerous scholarly
papers in prestigious journals such as Nature, Nature Biomedical
Engineering, and Cell. Professor Chen was elected as Fellow by the American
Association for the Advancement of Science (AAAS) for his outstanding
contributions to scientific research, technological innovation, education, and
public service.
Professor Chen stated, “Our laboratory aims to deeply explore efficient and diverse tumor treatment approaches. By leveraging Great Bay Bio’s extensive expertise in intelligent drug development, this collaboration will drive groundbreaking progress in the field of tumor-specific antibody discovery, providing cancer patients with more effective treatment solutions.”